Surprising MS Drug Approval: Time to Buy?
PTC Therapeutics shares soared recently after the EU issued a preliminary approval for the company's Duchenne muscular dystrophy (DMD) drug, Translarna. This caught the market by surprise, which explains the 59% gains over the course of 3 days. Is their still upside in Translarna, or would investors be better served taking a long look at one of its competitors?
The other two stocks attmepting to treat DMD are using a different approach from PTC and have had mixed results. Prosensa's (Nasdaq: RNA) drug failed a phase 3 trial and its big pharma partner walked away, while Sarepta (Nasdaq: SRPT) has promising enough mid-stage results that it is pushing for an accelerated approval from the FDA.
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass talk about Translarna's surprising approval and what it means for investors in PTC Therapeutics, Sarepta, and Prosensa.
Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
The article Surprising MS Drug Approval: Time to Buy? originally appeared on Fool.com.David Williamson owns shares of Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.